

## Product datasheet for **TF312113**

### IRF1 Human shRNA Plasmid Kit (Locus ID 3659)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	IRF1 Human shRNA Plasmid Kit (Locus ID 3659)
Locus ID:	3659
Synonyms:	IRF-1; MAR
Vector:	pRFP-C-RS (TR30014)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	IRF1 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 3659). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
RefSeq:	<a href="#">NM_002198</a> , <a href="#">NM_001354924</a> , <a href="#">NM_001354925</a> , <a href="#">NR_149068</a> , <a href="#">NR_149069</a> , <a href="#">NM_002198.1</a> , <a href="#">NM_002198.2</a> , <a href="#">BC009483</a> , <a href="#">BC009483.2</a> , <a href="#">NM_002198.3</a>
UniProt ID:	<a href="#">P10914</a>
Summary:	The protein encoded by this gene is a transcriptional regulator and tumor suppressor, serving as an activator of genes involved in both innate and acquired immune responses. The encoded protein activates the transcription of genes involved in the body's response to viruses and bacteria, playing a role in cell proliferation, apoptosis, the immune response, and DNA damage response. This protein represses the transcription of several other genes. As a tumor suppressor, it both suppresses tumor cell growth and stimulates an immune response against tumor cells. Defects in this gene have been associated with gastric cancer, myelogenous leukemia, and lung cancer. [provided by RefSeq, Aug 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).